Home » Topics » BioWorld Science, Dermatologic

BioWorld Science, Dermatologic
RSS

FDA removes clinical hold on Abeona's phase III VIITAL study of EB-101

Dec. 10, 2019

InMed receives CTA approval for phase I study of INM-755

Dec. 10, 2019

Phase III BE SURE study of bimekizumab in plaque psoriasis meets coprimary endpoints

Dec. 9, 2019

Healthy volunteer safety data reported from phase IIb study of EB-01 in allergic contact dermatitis

Dec. 4, 2019

BiomX completes enrollment in cosmetic clinical study of BX-001 in acne-prone skin

Dec. 3, 2019

Aslan reports preliminary proof-of-concept data on ASLAN-004 in atopic dermatitis

Dec. 2, 2019

Lilly initiates phase II study of LY-3454738 in chronic spontaneous urticaria

Nov. 28, 2019

Pfizer initiates first-in-human study of PF-07038124

Nov. 22, 2019

Arcutis begins phase II study of ARQ-154 foam for seborrheic dermatitis

Nov. 21, 2019

Celldex begins phase Ia study with KIT inhibitor CDX-0159

Nov. 20, 2019

Popular Stories

Today's news in brief
BioWorld
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...